Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib.

Endocrine - 1 Sept 2024

Chen Pu, Wang Jianling, Yao Yao, Qu Yiping, Ji Meiju, Hou Peng

Abstract excerpt

PURPOSE: The role of dual-specificity phosphatase-5 (DUSP5) in BRAF-mutant thyroid cancers remains unclear. The aims of this study are to investigate the role of DUSP5 in BRAF-mutant thyroid cancer cells, explore its value in the diagnosis and evaluate therapeutic potential of targeting DUSP5 combined with sorafenib for BRAF-mutant thyroid cancer patients. METHODS: The role of DUSP5 in thyroid cancer cells was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Dual-Specificity Phosphatases

Share to Proto-Oncogene Proteins B-raf

Share to Sorafenib

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 38564084
DOI: 10.1007/s12020-024-03801-8

Genes

DUSP5
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib.PMID 38564084Read ↗

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.Semantic proximity Read ↗

[Application of BRAF in the diagnosis and treatment of thyroid papillary carcinoma].Semantic proximity Read ↗

Dual-specific phosphatase 5 (DUSP5), upregulated in lung adenocarcinoma, as a potential therapeutic target for lung cancer.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibitionSemantic proximity Read ↗

Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.Semantic proximity Read ↗

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.Semantic proximity Read ↗

Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma.Semantic proximity Read ↗

DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.Semantic proximity Read ↗

Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.Semantic proximity Read ↗

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.Semantic proximity Read ↗

STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.